Atagabalin
Trans-dimethyl gababutin; UNII-JT7957Q2FB; 223445-75-8;
2-[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
2-[(3S,4S)-1-(aminomethyl)-3,4-dimethyl-cyclopentyl]acetic acid
3,4-trans-2-(1-(aminomethyl)-3,4-dimethylcyclopentyl)acetic acid
Cyclopentaneaceticacid, 1-(aminomethyl)-3,4-dimethyl-, (3S,4S)-
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).[1] It was under development as a treatment for insomnia,[2][3][4] but was discontinued following unsatisfactory trial results.
SYNTHESIS………………COMING UP SOON
References
1 Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). “Synthesis and in vivo evaluation of bicyclic gababutins”. Bioorganic & Medicinal Chemistry Letters 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.
- 2 Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). “Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit”. British Journal of Clinical Pharmacology 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.
- 3 Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). “Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology”. Brain Research 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMID 21664606.
- 4 Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). “Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models”. Pharmaceutical Research 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607.
| Patent | Submitted | Granted |
|---|---|---|
| Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors [US7572799] | 2005-11-03 | 2009-08-11 |
| Substituted morpholine compounds for the treatment of central nervous system disorders [US7659394] | 2005-11-03 | 2010-02-09 |
| Therapeutic pyrazolo[3,4-B]pyridines and indazoles [US7423054] | 2006-06-01 | 2008-09-09 |
| Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same [US7312233] | 2006-09-14 | 2007-12-25 |
| Compounds useful in therapy [US7482375] | 2006-10-26 | 2009-01-27 |
| Therapeutic pyrazolo[3,4-b]pyridines and indazoles [US7485636] | 2006-09-28 | 2009-02-03 |
| Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists [US7566739] | 2006-09-14 | 2009-07-28 |
| Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same [US7576099] | 2006-08-31 | 2009-08-18 |
| Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists [US7622589] | 2006-09-21 | 2009-11-24 |
| Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders [US2009203782] | 2009-08-13 |
|
|
| Systematic (IUPAC) name | |
|---|---|
|
[(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid
|
|
| Identifiers | |
| CAS Registry Number | 223445-75-8  |
| ATC code | None |
| PubChem | CID: 9794485 |
| ChemSpider | 7970252  |
| UNII | JT7957Q2FB |
| ChEMBL | CHEMBL593430 |
| Chemical data | |
| Formula | C10H19NO2 |
| Molecular mass | 185.263 g/mol |
//////C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN
READ IMAGABALIN, PD 217074
Filed under: Uncategorized Tagged: Atagabalin
